Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

- First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion -

ORLANDO, Fla., March 30 /PRNewswire/ -- Amorcyte, Inc. (Amorcyte) today announced data from its Phase I clinical trial of AMR-001, the company's lead product for the treatment of damaged heart muscle following acute myocardial infarction (AMI), that showed a significant relationship between cell dose and biologic effect. This is the first and only study to prospectively define a dose of a purified and potent autologous stem cell therapy (AMR-001) that resulted in a significant improvement in perfusion, a trend towards improved cardiac function and the potential to reduce subsequent adverse cardiac events following AMI. The findings were presented at the American College of Cardiology (ACC) Annual Scientific Session.

The 31 patients in the Phase I trial were randomly assigned to an autologous stem cell harvest group (cells were harvested from the patient's own bone marrow) or control group five days after an ST elevation myocardial infarction (STEMI) characterized by a prolonged period of hypoperfusion (blocked blood supply). CD34+ cells were then isolated from the bone marrow, and enriched to increase potency using the company's patented technology into five, 10 and 15 million cell doses. The cells were infused via the infarct-related artery seven to 11 days following the STEMI - the optimal time frame to attempt to prevent adverse ventricular remodeling. Caused by the progressive decline in heart muscle function following an AMI, ventricular remodeling can lead to permanent heart damage and increase the risk of recurrent heart attack, other adverse cardiac events and death.

The study results showed that patients receiving 10 to 15 million cells (n=9) experienced significant improvement in resting perfusion rates at six months as compared to patients receiving 5 million cells (n=6) and control (n=15), as measu
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... -- Rhythm, a biopharmaceutical company developing peptide therapeutics that ... metabolic disorders, announced today that it has filed a ... and Exchange Commission (SEC) relating to the proposed initial ... number of shares to be offered and the price ... Citigroup and Cowen and Company will act ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... repairing damaged human tissue doesn,t wrinkle up when it ... of California, San Diego marks a significant breakthrough in ... of native human tissue. Shaochen Chen, professor ... Diego Jacobs School of Engineering, hopes future tissue patches, ...
... Mass., May 26, 2011 New England Biolabs (NEB), ... reagents for the life science industry, extends its global ... France, located at Bioparc Genopole in Evry, just south ... Ellard, President and CEO of NEB Inc., was on ...
... 2011 Addressing the issue of data overload from next-generation ... ) today launched its LifeScope™ 2.0 Genomic Analysis Software ... genomic sequencing instruments to study human disease such as cancer. ... A single next generation sequencing instrument can generate nearly 200 ...
Cached Biology Technology:Nanoengineers invent new biomaterial that more closely mimics human tissue 2New England Biolabs Opens New Subsidiary Office in France 2Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 2Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 3Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 4Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 5
(Date:8/27/2014)... The mechanical force that a single fungal cell or bacterial ... but it plays a heavy role in setting up some ... it may not be too much of a stretch to ... the ability to respond to the touch of beneficial fungi, ... professor of agronomy at the University of Wisconsin-Madison. , ...
(Date:8/27/2014)... Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... sold in the offering consists of 2,000 shares of ...
(Date:8/27/2014)... of North America,s megafauna mastodons, short-faced bears, giant ... disappeared close to 13,000 years ago at the ... massive extinction has long been debated by scientists who, ... A group of scientists, including UC Santa Barbara,s James ... posited that a comet collision with Earth played a ...
Breaking Biology News(10 mins):A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... expect to live slightly longer than Europeans. This has since ... now live about a year-and-a-half less, on average, than their ... other developed nations. How did Americans fall behind? A ... & Medicine is the first to calculate the fiscal ...
... shows the prevalence of gout in the U.S. has risen ... (4%) Americans. Prevalence of increased uric acid levels (hyperuricemia) also ... frequency of obesity and hypertension may be associated with the ... in Arthritis & Rheumatism , a journal published by ...
... east coast of Canada are showing signs of recovery more ... 1990s, according to research published today in Nature . ... an ecosystem that was pushed out of balance and that ... professor in the Department of Biology, former principal at Queen,s, ...
Cached Biology News:Getting 50-year-old Americans as healthy as Europeans could save Medicare and Medicaid $632 billion by 2050 2Gout prevalence swells in US over last 2 decades 2Cod resurgence in Canadian waters 2
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
...
...
Biology Products: